AlcoholNCT07852013
Eye-Tracking Alcohol Warning
A study testing Alcohol Cancer Warning Labels in people with Alcohol, run by University of Miami at 1 site in United States.
Trial summary
This pilot study will evaluate communication strategies that may improve public understanding of alcohol-related cancer risks and influence behavioral intentions. The study will compare graphic alcohol cancer warning labels with the current U.S. Surgeon General text-only warning label across two stages. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Alcohol
- What is being tested?
- Alcohol Cancer Warning Labels
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2026to 1 Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 21 years
- Regular alcohol consumers (≥ 2 drinks per week)
- US residence
- Able to read and understand English
- Able and willing to provide informed consent
- Able to wear eyeglasses
Who cannot join
- Are not regular alcohol consumers (< 2 drinks per week)
- Are unable to complete study procedures due to cognitive or physical limitations
- Decline or withdraw informed consent
- Pregnant women, prisoners, persons not residing in the US, and non-alcohol users
- Have eye conditions or impairments that prevent reliable eye-tracking (e.g., severe nystagmus or uncorrectable visual impairment)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Miami - Rosenstiel Medical Science Building
Miami, Florida, 33136
Taghrid Asfar, Principal Investigator, MD, MPH, 305-243-3826, tasfar@miami.edu
Maria Fernanda Garcia Morillo, B.S., 5615697987, mfg136@med.miami.edu
About this study
Official title: Eye-Tracking and Discrete Choice Experiments Testing Alcohol Cancer Risk Warning Labels: Implications for Policy
This pilot study will evaluate communication strategies that may improve public understanding of alcohol-related cancer risks and influence behavioral intentions. The study will compare graphic alcohol cancer warning labels with the current U.S. Surgeon General text-only warning label across two stages. The first stage is an in-person, lab-based eye-tracking experiment that will examine differences in visual attention, communication outcomes, harm perception, and behavioral intentions following exposure to graphic versus text-only warning labels. The second stage is a discrete choice experiment that will examine how warning label type, warning label size, and alcohol type (beer, wine, or liquor) influence participants' intentions to reduce or stop alcohol consumption and purchase alcohol. The study will recruit 50 adults aged 21 years or older who report regular alcohol consumption.
- Conditions
- Alcohol
- Being tested
- Alcohol Cancer Warning Labels
- Keywords
- Cancer, Alcohol Warning Labels, Graphic Warning Labels, Eye-Tracking, Discrete Choice Experiment, Cancer Risk Communication
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Alcohol Cancer Warning LabelsBehavioural
Participants will be exposed to alcohol-cancer warning labels during two sequential study states. Stage 1 consists of Eye-Tracking Experiment in which participants will be exposed to six alcohol warning-label stimuli, including graphic alcohol cancer warning labels and Surgeon General text-only warning labels displayed on beer, wine, and liquor containers. Each participant will view all six warning-label stimuli for 15 seconds each in a randomized, counterbalanced order while visual attention is measured using eye-tracking technology. Stage 2 consist of the Discrete Choice Experiment in which participants will choose between 18 randomly presented choice sets. Choice sets will vary by warning label type, warning label size, and alcohol type (beer, wine, or liquor). Participants' responses will be used to assess preferences and behavioral reactions to different alcohol warning-label characteristics.
| Study group | Role | What they receive |
|---|---|---|
| Alcohol Warning Label Exposure | Experimental | Participants will complete a 2-stage behavioral experiment during a single study visit.
Stage 1 Eye-Tracking Experiment:
Participants will complete an eye-tracking experiment during which they will view six alcohol warning-label stimuli presented one at a time in a randomized, counterbalanced order. The stimuli include graphic and text-only warning labels displayed on beer, wine, and liquor containers.
Stage 2 Discrete Choice Experiment:
Following completion of the eye-tracking experiment, participants will complete a discrete choice experiment consisting of 18 randomly presented choice sets that vary by warning label type, warning label size, and alcohol type. Participants' responses will be used to assess preferences and behavioral reactions to different alcohol warning-label characteristics. Receives: Behavioral: Alcohol Cancer Warning Labels |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Attention Metrics
Visual attention to predefined areas of interest (AOIs) containing graphic and text-only alcohol warning labels on alcohol beverage container stimuli will be assessed using eye-tracking. Outcome measures include: (1) time to first fixation (milliseconds), defined as the elapsed time from stimulus presentation to the participant's first fixation on an AOI; (2) visit count, defined as the number of visits to an AOI; and (3) dwell time (milliseconds), defined as the cumulative duration of fixations within an AOI. Higher visit counts and dwell times indicate greater visual attention to the warning label.
Measured: During Stage 1 of the single study visit, approximately 35-45 minutes
Intention to Reduce Alcohol Consumption in the Next 30 Days
Participants will select between warning label alternatives that vary by warning label type, warning label size, and alcohol type. The outcome will be measured as the frequency or probability of selecting warning label alternatives perceived as most likely to increase intentions to reduce alcohol consumption within the next 30 days.
Measured: During Stage 2 of the single study visit, approximately 10-20 minutes
Secondary outcomes (5)
Emotional Reactions to Alcohol Warning Labels
Emotional reactions following exposure to the warning labels will include believability, avoidance, cognitive elaboration, and negative affective responses. Believability will be assessed on a scale from 1 (strongly disagree) to 5 (strongly agree). Avoidance will be assessed as yes/no. Cognitive elaboration will be assessed using three items on a scale from 1 (not at all) to 5 (very much), with higher scores indicating greater cognitive processing of the warning label message.. Negative affect will be assessed using five items on a scale from 1 (not at all) to 5 (very much),with higher scores indicating greater negative emotional response.
Measured: After each warning-label exposure during Stage 1 of the single study visit, approximately 35-45 minutes
Change in Harm Perception
Change in harm perception will be assessed with one item asking how worried the participant is that alcohol drinking puts them at risk of cancer in the future, on a scale from 1 (not worried) to 5 (very worried).
Measured: "Baseline" or "Day 1"
Change in Behavioral Intentions Toward Alcohol Consumption
Change in behavioral intentions will be assessed with three items asking to what extent participants are determined to (i) reduce, (ii) completely stop, and (iii) commit to limiting their alcohol intake in the next 30 days, on a scale from 0 to 5, with higher scores indicating stronger intentions to modify alcohol consumption
Measured: "Baseline" or "Day 1"
Intention to Stop Alcohol Consumption in the Next 30 Days
Participants will select the warning label option most likely to increase their intention to stop alcohol consumption in the next 30 days. Warning label alternatives vary by warning label type, warning label size, and alcohol type. The outcome will be measured as the frequency of selecting warning label alternatives perceived as most likely to increase intentions to stop alcohol consumption within the next 30 days.
Measured: During Stage 2 of the single study visit, approximately 10-20 minutes
Intention to Purchase Alcohol Products in the Next 30 Days
Participants will select the warning label option most likely to decrease their intention to purchase alcohol products in the next 30 days. Warning label alternatives vary by warning label type, warning label size, and alcohol type. The outcome will be measured as the frequency of selecting warning label alternatives perceived as most likely to decrease intentions to purchase alcohol products within the next 30 days.
Measured: During Stage 2 of the single study visit, approximately 10-20 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study startNov 2026 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AlcoholStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All participants will complete a within-subject eye-tracking experiment followed by a discrete choice experiment. During the eye-tracking experiment, each participant will be exposed to all six warning-label stimuli in a randomized and counterbalanced order. After completing the eye-tracking experiment, participants will complete the discrete choice experiment.
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Miami
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Taghrid Asfar, University of Miami
- Investigators
- Taghrid Asfar, MD, MSPH, Principal investigator, University of Miami
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07852013
- Sponsor's protocol ID
- 20260643
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Eye-Tracking and Discrete Choice Experiments Testing Alcohol Cancer Risk Warning Labels: Implications for Policy
- ClinicalTrials.gov ID
- NCT07852013
- Acronym / sponsor ID
- 20260643
- Conditions
- Alcohol
- Keywords
- Cancer, Alcohol Warning Labels, Graphic Warning Labels, Eye-Tracking, Discrete Choice Experiment, Cancer Risk Communication
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of MiamiUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Oct 2027 (estimated)
- First posted
- 1 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot study will evaluate communication strategies that may improve public understanding of alcohol-related cancer risks and influence behavioral intentions. The study will compare graphic alcohol cancer warning labels with the current U.S. Surgeon General text-only warning label across two stages. The first stage is an in-person, lab-based eye-tracking experiment that will examine differences in visual attention, communication outcomes, harm perception, and behavioral intentions following exposure to graphic versus text-only warning labels. The second stage is a discrete choice experiment that will examine how warning label type, warning label size, and alcohol type (beer, wine, or liquor) influence participants' intentions to reduce or stop alcohol consumption and purchase alcohol. The study will recruit 50 adults aged 21 years or older who report regular alcohol consumption.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All participants will complete a within-subject eye-tracking experiment followed by a discrete choice experiment. During the eye-tracking experiment, each participant will be exposed to all six warning-label stimuli in a randomized and counterbalanced order. After completing the eye-tracking experiment, participants will complete the discrete choice experiment.
| Arm | Type | Receives |
|---|---|---|
| Alcohol Warning Label Exposure | Experimental | Behavioral: Alcohol Cancer Warning LabelsParticipants will complete a 2-stage behavioral experiment during a single study visit. Stage 1 Eye-Tracking Experiment: Participants will complete an eye-tracking experiment during which they will view six alcohol warning-label stimuli presented one at a time in a randomized, counterbalanced order. The stimuli include graphic and text-only warning labels displayed on beer, wine, and liquor containers. Stage 2 Discrete Choice Experiment: Following completion of the eye-tracking experiment, participants will complete a discrete choice experiment consisting of 18 randomly presented choice sets that vary by warning label type, warning label size, and alcohol type. Participants' responses will be used to assess preferences and behavioral reactions to different alcohol warning-label characteristics. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 21 years
- Regular alcohol consumers (≥ 2 drinks per week)
- US residence
- Able to read and understand English
- Able and willing to provide informed consent
Key exclusion criteria (5 listed)
- Are not regular alcohol consumers (< 2 drinks per week)
- Are unable to complete study procedures due to cognitive or physical limitations
- Decline or withdraw informed consent
- Pregnant women, prisoners, persons not residing in the US, and non-alcohol users
- Have eye conditions or impairments that prevent reliable eye-tracking (e.g., severe nystagmus or uncorrectable visual impairment)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Alcohol Cancer Warning LabelsParticipants will be exposed to alcohol-cancer warning labels during two sequential study states. Stage 1 consists of Eye-Tracking Experiment in which participants will be exposed to six alcohol warning-label stimuli, including graphic alcohol cancer warning labels and Surgeon General text-only warning labels displayed on beer, wine, and liquor containers. Each participant will view all six warning-label stimuli for 15 seconds each in a randomized, counterbalanced order while visual attention is measured using eye-tracking technology. Stage 2 consist of the Discrete Choice Experiment in which participants will choose between 18 randomly presented choice sets. Choice sets will vary by warning label type, warning label size, and alcohol type (beer, wine, or liquor). Participants' responses will be used to assess preferences and behavioral reactions to different alcohol warning-label characteristics. | Behavioural | Alcohol Warning Label Exposure |
Primary outcome
Visual Attention Metrics
Time frame: During Stage 1 of the single study visit, approximately 35-45 minutes
Visual attention to predefined areas of interest (AOIs) containing graphic and text-only alcohol warning labels on alcohol beverage container stimuli will be assessed using eye-tracking. Outcome measures include: (1) time to first fixation (milliseconds), defined as the elapsed time from stimulus presentation to the participant's first fixation on an AOI; (2) visit count, defined as the number of visits to an AOI; and (3) dwell time (milliseconds), defined as the cumulative duration of fixations within an AOI. Higher visit counts and dwell times indicate greater visual attention to the warning label.
Intention to Reduce Alcohol Consumption in the Next 30 Days
Time frame: During Stage 2 of the single study visit, approximately 10-20 minutes
Participants will select between warning label alternatives that vary by warning label type, warning label size, and alcohol type. The outcome will be measured as the frequency or probability of selecting warning label alternatives perceived as most likely to increase intentions to reduce alcohol consumption within the next 30 days.
5 secondary outcomes
Emotional Reactions to Alcohol Warning Labels
Time frame: After each warning-label exposure during Stage 1 of the single study visit, approximately 35-45 minutes
Change in Harm Perception
Time frame: "Baseline" or "Day 1"
Change in Behavioral Intentions Toward Alcohol Consumption
Time frame: "Baseline" or "Day 1"
Intention to Stop Alcohol Consumption in the Next 30 Days
Time frame: During Stage 2 of the single study visit, approximately 10-20 minutes
Intention to Purchase Alcohol Products in the Next 30 Days
Time frame: During Stage 2 of the single study visit, approximately 10-20 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Alcohol
Not yet recruitingEarly Phase 1
Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder
Opioid Use Disorder, Alcohol Intoxication
RecruitingPhase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
Alcohol Drinking
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
RecruitingPhase 2
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
Not yet recruitingEarly Phase 1
Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women
Sexual Assault, Alcohol Intoxication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Taghrid Asfar, MD, MSPH principal investigator
University of Miami
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Alcohol Cancer Warning Labels in people with Alcohol, run by University of Miami at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Taghrid Asfar, MD, MSPH ((305) 243-3826, tasfar@miami.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Attention Metrics (time frame: During Stage 1 of the single study visit, approximately 35-45 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.